Kathy Johnson Weiler Sells 14,150 Shares of AxoGen (NASDAQ:AXGN) Stock

Key Points

• AxoGen director Kathy Johnson Weiler sold 14,150 shares at an average price of $45.30, generating $640,995. The transaction was made under a pre-arranged Rule 10b5-1 trading plan.
• AxoGen shares recently traded at $48.48, near their 12-month high of $49.12. The company reported quarterly revenue of $69.73 million and adjusted earnings of $0.12 per share, matching analyst expectations for EPS and exceeding revenue estimates.
• Wall Street maintains a generally positive outlook, with nine analysts rating the stock a Buy and a consensus price target of $51.00. Institutional investors own approximately 80.29% of AxoGen’s shares, with several major funds adding positions recently.

AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) Director Kathy Johnson Weiler sold 14,150 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $45.30, for a total transaction of $640,995.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

AxoGen Trading Up 0.5%

NASDAQ AXGN traded up $0.26 on Tuesday, reaching $48.48. The stock had a trading volume of 576,927 shares, compared to its average volume of 1,114,968. The firm has a market capitalization of $2.61 billion, a price-to-earnings ratio of -71.29 and a beta of 1.11. The company has a quick ratio of 5.04, a current ratio of 6.60 and a debt-to-equity ratio of 0.07. AxoGen, Inc. has a 12-month low of $13.64 and a 12-month high of $49.12. The stock has a fifty day moving average price of $42.83 and a two-hundred day moving average price of $38.03.

AxoGen (NASDAQ:AXGN - Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.12 EPS for the quarter, hitting the consensus estimate of $0.12. AxoGen had a negative return on equity of 8.90% and a negative net margin of 13.36%.The business had revenue of $69.73 million during the quarter, compared to analyst estimates of $67.10 million. As a group, sell-side analysts forecast that AxoGen, Inc. will post -0.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on AXGN. Jefferies Financial Group reissued a "buy" rating and set a $55.00 price target on shares of AxoGen in a research report on Wednesday, July 29th. Canaccord Genuity Group raised their price target on shares of AxoGen from $50.00 to $55.00 and gave the company a "buy" rating in a research report on Thursday, July 30th. Raymond James Financial restated an "outperform" rating and issued a $48.00 price target on shares of AxoGen in a research note on Wednesday, April 29th. Citigroup reaffirmed a "market outperform" rating on shares of AxoGen in a research report on Thursday, July 30th. Finally, Zacks Research upgraded AxoGen from a "strong sell" rating to a "hold" rating in a research note on Friday, May 29th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $51.00.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Edmond DE Rothschild Holding S.A. purchased a new stake in AxoGen during the second quarter worth approximately $1,469,000. Lisanti Capital Growth LLC purchased a new stake in AxoGen in the second quarter valued at $4,183,000. Tocqueville Asset Management L.P. purchased a new position in shares of AxoGen during the second quarter worth about $8,032,000. BlackRock Inc. purchased a new position in shares of AxoGen during the second quarter worth about $204,123,000. Finally, Deutsche Bank AG purchased a new stake in shares of AxoGen in the 2nd quarter valued at about $30,106,000. Hedge funds and other institutional investors own 80.29% of the company's stock.

About AxoGen

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen's offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company's core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source